Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!

NETRF Funded Research Projects

PRESCIENT – PET REsponSe CrItEria for Neuroendocrine Tumors

Lisa Bodei, MD, PhD

Preclinical toxicity and therapy study of 225Ac-crown-TATE

Paul Schaffer, PhD

Phase I/II Study of Intratumoral Ipilimumab with Anti-PD-L1 in Patients with Advanced, Progressive, Well-Differentiated NETS

Pamela Kunz, MD

Phase 1 study of SurvaxM in survivin positive nets

Renuka Iyer, MD

Patrícia Ribeiro Pereira, Ph.D.

PANNET MODELING, MECHANISMS, AND EXPERIMENTAL TREATMENT

James Bibb, PhD

About
NETRF

Our Story

NETRF Team

Board of Directors

Board of Scientific Advisors

Diversity & Inclusion

Financial Stewardship & Accountability

Careers at NETRF

2024 Annual Report

For Researchers

About our Research

Our Strategy

Our Impact

Research Portfolio

Funding for Researchers

Apply for Grants

Research Symposium

Get
Involved

Support NET Research

Give Now

Ways to Give

What Your Gift Supports

Donor Stories

Community Fundraising

Memorial Gifts

Everlasting Impact Tributes

Planned Giving

NETRF Funded Research Projects

PRESCIENT – PET REsponSe CrItEria for Neuroendocrine Tumors

Preclinical toxicity and therapy study of 225Ac-crown-TATE

Phase I/II Study of Intratumoral Ipilimumab with Anti-PD-L1 in Patients with Advanced, Progressive, Well-Differentiated NETS

Phase 1 study of SurvaxM in survivin positive nets

Patrícia Ribeiro Pereira, Ph.D.

PANNET MODELING, MECHANISMS, AND EXPERIMENTAL TREATMENT

About NETRF

For Researchers

Get Involved

NETRF Funded Research Projects

PRESCIENT – PET REsponSe CrItEria for Neuroendocrine Tumors

Preclinical toxicity and therapy study of 225Ac-crown-TATE

Phase I/II Study of Intratumoral Ipilimumab with Anti-PD-L1 in Patients with Advanced, Progressive, Well-Differentiated NETS

Phase 1 study of SurvaxM in survivin positive nets

Patrícia Ribeiro Pereira, Ph.D.

PANNET MODELING, MECHANISMS, AND EXPERIMENTAL TREATMENT

About
NETRF

Get
Involved